Business Description
Bright Minds Biosciences Inc
NAICS : 325410
SIC : 3741
ISIN : CA10919W4056
Share Class Description:
XCNQ:DRUG: Ordinary SharesTotal Employee Number:
25Description
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4664.08 | |||||
Equity-to-Asset | 0.99 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 30.7 | |||||
3-Year EPS without NRI Growth Rate | 33.2 | |||||
3-Year FCF Growth Rate | 38.8 | |||||
3-Year Book Growth Rate | 53 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.9 | |||||
9-Day RSI | 50.26 | |||||
14-Day RSI | 52.47 | |||||
3-1 Month Momentum % | -6.71 | |||||
6-1 Month Momentum % | -11.57 | |||||
12-1 Month Momentum % | 78.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 121.97 | |||||
Quick Ratio | 121.97 | |||||
Cash Ratio | 121 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.5 | |||||
Shareholder Yield % | -22.84 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -14.6 | |||||
ROA % | -14.41 | |||||
ROIC % | -14144.6 | |||||
3-Year ROIIC % | -10370 | |||||
ROC (Joel Greenblatt) % | -30768.39 | |||||
ROCE % | -23.42 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.49 | |||||
Price-to-Tangible-Book | 3.49 | |||||
EV-to-EBIT | -19.47 | |||||
EV-to-EBITDA | -19.51 | |||||
EV-to-Forward-EBITDA | -2.97 | |||||
EV-to-FCF | -33.14 | |||||
Price-to-Projected-FCF | 7.09 | |||||
| Price-to-Net-Current-Asset-Value | 3.49 | |||||
| Price-to-Net-Cash | 3.52 | |||||
Earnings Yield (Greenblatt) % | -5.14 | |||||
FCF Yield % | -2.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bright Minds Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -2.88 | ||
| Beta | -9.4912 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 31.33 | ||
| Volatility % | 61.78 | ||
| 14-Day RSI | 52.47 | ||
| 14-Day ATR (C$) | 3.899418 | ||
| 20-Day SMA (C$) | 107.765 | ||
| 12-1 Month Momentum % | 78.21 | ||
| 52-Week Range (C$) | 53.99 - 170 | ||
| Shares Outstanding (Mil) | 9.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bright Minds Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bright Minds Biosciences Inc Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2027-02-12 | In 175 days | ||
| Annual report for 2026 | 2026-12-23 | In 124 days | ||
| Third quarter earnings results for 2026 | 2026-08-14 | 109.72 (-1.85%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 16:20 | 106.82 (-0.74%) | ||
| Second quarter earnings results for 2026 | 2026-05-19 | 104.89 (-0.96%) | ||
| General meeting for 2026 | 2026-03-31 10:00 | 95.41 (-4.59%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 09:10 | 108.64 (-0.15%) | ||
| First quarter earnings results for 2026 | 2026-02-12 | 105.46 (+0.74%) | ||
| Topline results for Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy | 2026-01-06 08:00 | 104.00 (-11.89%) | ||
| Annual report for 2025 | 2025-12-23 | 114.23 (-1.53%) |
Show
Entries
Bright Minds Biosciences Inc Frequently Asked Questions
What is Bright Minds Biosciences Inc(XCNQ:DRUG)'s stock price today?
The current price of XCNQ:DRUG is C$109.41. The 52 week high of XCNQ:DRUG is C$170.00 and 52 week low is C$53.99.
When is next earnings date of Bright Minds Biosciences Inc(XCNQ:DRUG)?
The next earnings date of Bright Minds Biosciences Inc(XCNQ:DRUG) is 2026-11-14 Est..
Does Bright Minds Biosciences Inc(XCNQ:DRUG) pay dividends? If so, how much?
Bright Minds Biosciences Inc(XCNQ:DRUG) does not pay dividend.
Press Release
Articles on Bright Minds Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers